These EU Biotechs presented groundbreaking results at World Biggest Cancer Meeting

21/04/2016 - 5 minutes

The annual meeting of the American Association for Cancer Research (AACR) has just finished. From Europe, who made a splash with their results?

american_association_cancer_research_biotech_eu_2016The AACR annual meeting is the world’s biggest conference in Cancer research, and the must-attend event for Biotechs developing cancer therapies.

The 2016 edition took place in New Orleans (US) from the 16th to the 20th of April, and presented over 6,000 works of research in the Cancer field. Four of these come from European Biotechs, which obviously caught our attention…

So here’s a quick summary of the 2016 AACR presentations by EU biotechs…

 

aarc_2016_transgene_oncolytic_virus_immunotherapy

Transgene is based in Strabourg and is actually the oldest Biotech in France. After years of struggling and going from recombinant proteins to gene therapy, Transgene’s focus on oncolytic virus seems to have finally paid off.

At the AACR, Transgene presented preclinical data (poster here) for a new generation oncolytic viral immunotherapy.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member